MeiraGTx(US:MGTX) Globenewswireยท2025-10-07 12:00Core Insights - MeiraGTx Holdings plc is showcasing two posters at the ESGCT 2025 Annual Congress, focusing on advancements in gene therapy and AAV manufacturing processes [1][2]. Group 1: Poster Presentations - The first poster (P0089) discusses the development of novel AAV capsids for intravitreal delivery, validated in human retinal organoids, showing over 2-fold higher transduction efficiency compared to AAV2.7m8 [2][5][6]. - The second poster (P0170) details the scale-up of a perfusion-based AAV manufacturing process to 40L bioreactors, achieving a 120% increase in volumetric VG yield and a 2.2-fold reduction in cost-of-goods per dose [7][8]. Group 2: Company Overview - MeiraGTx is a clinical-stage genetic medicines company with a diverse pipeline, including four late-stage clinical programs targeting inherited retinal disorders, Parkinson's disease, and radiation-induced xerostomia [9]. - The company has developed a proprietary manufacturing platform over nine years, focusing on optimizing capsids and viral vectors, with five global facilities, including two licensed for GMP production [9].